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Objective: Many patients present to their physician with depression as their primary symptom. 
However, depression may mask other comorbid disorders. This article presents diagnostic 
criteria and treatment recommendations (and monitoring) pertaining to the diagnosis of adult 
attention deﬁ  cit hyperactivity disorder (ADHD), which may be missed in patients who present 
with depressive symptoms, or major depressive disorder (MDD). Other co-occurring conditions 
such as anxiety, substance use, and bipolar disorder are brieﬂ  y discussed.
Methods: A panel of psychiatrist-clinicians with expertise in the area of child and adolescent 
ADHD and mood disorders, adult mood disorders, and adult ADHD was convened. A literature 
search for recommendations on the diagnosis and treatment of co-occurring conditions (MDD, 
anxiety symptoms, and substance use) with adult ADHD was performed. Based on this, and the 
panel’s clinical expertise, the authors developed a diagnostic algorithm and recommendations 
for the treatment of adult ADHD with co-occurring MDD.
Results: Little information exists to assist clinicians in diagnosing ADHD co-occurring with 
other disorders such as MDD. A three-step process was developed by the panel to aid in the 
screening and diagnosis of adult ADHD. In addition, comorbid MDD, bipolar disorder, anxiety 
symptoms, substance use and cardiovascular concerns regarding stimulant use are discussed.
Conclusion: This article provides clinicians with a clinically relevant overview of the literature 
on comorbid ADHD and depression and offers a clinically useful diagnostic algorithm and 
treatment suggestions.
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Introduction
Attention deﬁ  cit hyperactivity disorder (ADHD) is a common neurodevelopmental 
disorder of childhood associated with substantial cognitive, family, social, behavioral, 
and academic impairment. ADHD in childhood occurs in an estimated 3%–7% of 
school-aged children.1–4 The National Comorbidity Survey Replication Study found 
36% of adults who met the criteria for ADHD as children continued to meet the 
diagnostic criteria as adults.5–7 The overall prevalence of adults who meet the diagnosis 
of ADHD was 4.4%.8 The Cross National Prevalence study estimated an average adult 
ADHD prevalence of 3.4% with lower income countries reporting a lower prevalence 
(1.9%) than higher income countries (4.2%). The survey states few cases are treated 
for ADHD but in many cases treatment is given for comorbid disorders.9
Many clinicians are familiar with making a diagnosis of ADHD in young people 
but ﬁ  nd that making a diagnosis of ADHD in adults presents challenges. First, the 
Diagnostic and Statistical Manual (DSM) requirement of onset prior to age seven 
relies on the memory of the informant and retrospective accounts of symptoms are 
notoriously inaccurate.10,11 In addition, the ancillary information such as school reports 
that is helpful in diagnosing childhood ADHD is frequently not available for adults.Neuropsychiatric Disease and Treatment 2009:5 138
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Furthermore, the presentation of ADHD in adults may 
be obfuscated by outcomes of the chronic illness such as 
demoralization and substance misuse.12–16 Finally, adults 
often underreport their symptoms. This might be due to the 
lifelong presence of the symptoms, which are now considered 
part of their personal style rather than abnormal or due to the 
adaptations they have made to accommodate their symptoms, 
such as careful job selection.
Clinicians who treat children with ADHD do not usually 
follow their patients into adulthood, and those who treat 
adults are not always familiar with the diagnosis or usual 
management.4 Hence, in the opinion of the panel, clinicians 
treating adults might assume affected individuals have, 
by adulthood, grown out of the disorder. The panel also 
suggested clinicians treating adults may be more familiar 
with mood and anxiety symptoms. As a result, they may tend 
to make a mood or anxiety disorder diagnosis rather than 
attribute the presenting symptoms to ADHD. Some adult 
patients present with self-identiﬁ  ed ADHD, and this may 
arouse suspicion among clinicians concerned these patients 
are either malingering or susceptible to media inﬂ  uence.4 
Clinicians may also be concerned that patients are seeking 
treatment as a way to obtain medications they can misuse or 
abuse. Although some clinicians have challenged the validity 
of the diagnosis, the evidence supports the existence of adult 
ADHD.5–8 Until recently, adult ADHD was not included in 
medical school curricula or in postgraduate medical training 
and many health providers are therefore unfamiliar with the 
diagnosis and management of adult ADHD, in particular 
when it occurs in conjunction with psychiatric disorders such 
as major depressive disorder (MDD).
This article reviews the available literature pertaining to 
the diagnosis of adult ADHD and recommends diagnostic 
criteria and treatment guidelines based on consensus by the 
panel. In addition, comorbid depression, bipolar disorder, 
anxiety symptoms, substance use, and cardiovascular 
concerns regarding stimulant use are discussed with a view 
to providing consensus guidance on how to manage these 
patients.
Methods
In 2007, the Canadian Psychiatric Association’s (CPA) 
needs assessment identiﬁ  ed ADHD as an area warrant-
ing professional attention. In partnership with the CPA, 
the Ofﬁ  ce of Continuing Medical Education and Profes-
sional Development (CME and PD) at the University of 
Calgary, and Partners In Psychiatry sent survey invitations to 
psychiatrists and family practitioners. In all, 517 Canadian 
physicians responded to the survey. Results indicate 
family physicians and psychiatrists have a desire for more 
knowledge regarding ADHD including adult ADHD and 
comorbidities.
In response, a group of Canadian psychiatrists with clini-
cal experience in the diagnosis and treatment of adult ADHD, 
adult MDD and childhood ADHD/MDD were invited by 
Janssen-Ortho Inc., to address the issue of diagnosis and man-
agement of adult ADHD co-occurring with Major Depressive 
Disorder and provide some guidance for other key psychi-
atric illnesses (eg, anxiety disorder, substance use, bipolar 
disorder). Members of the panel identiﬁ  ed the clinically rel-
evant diagnostic and treatment issues and critically reviewed 
the available literature. The panel synthesized relevant 
information obtained from the literature review and reached 
consensus on clinically relevant information arising from the 
review. The panel, via teleconference or email, discussed 
areas of disagreement until consensus was reached. A “ﬁ  rst 
draft” of an academic paper was developed by a professional 
writer from the consensus discussion and the literature and 
was reviewed by all panel members, followed by revisions 
and a ﬁ  nal consensus on the manuscript by all members of 
the panel. Janssen Ortho Inc. employees observed the ﬁ  rst 
expert panel meeting, reviewed the literature and gave input 
into the article.
Literature review
A search of the literature was performed in March 2008 and 
repeated in August 2008. The databases EmBase, Medline, 
and Psychinfo were searched over the period of 1990–2008; 
keywords: ADHD adult, depression, comorbid, bipolar 
disorder and ADHD, ADHD and substance use, ADHD and 
depressive disorder differentiation.
Key learning issue #1: ADHD persists 
into adulthood
Historical teachings that ADHD rarely persists into adulthood 
are not supported by the research data. A longitudinal study 
of 85 children with ADHD found that 4% continued to meet 
diagnostic criteria for ADHD as adults.17 Another study of 
104 boys with ADHD found that 11% had disabling ADHD 
in adulthood.17,18 Other studies have reported that 60% of 
children with ADHD will exhibit sub-clinical symptoms 
of ADHD4,6,19–22 in adulthood. ADHD is best understood as 
a childhood-onset neurodevelopmental disorder that may 
persist into adulthood.19
Adult ADHD prevalence estimates vary from 1%–6% 
depending on the populations studied (community versus Neuropsychiatric Disease and Treatment 2009:5 139
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clinic), the edition of Diagnostic and Statistical Manual 
(DSM) used, and whether the assessment was based on self or 
observer report. As well, differing deﬁ  nitions of persistence 
were employed. Persistence may be deﬁ  ned as continuing 
to meet the full DSM criteria, or continuing to experience 
functional impairment due to the ADHD symptoms.8,19,22,23 
The most recent estimate of the prevalence of adult ADHD 
from the National Comorbidity Survey Replication (USA) 
was 4.4%.8
Many adults living with ADHD were not diagnosed 
or effectively treated as children.2,13,24 Early clinical work 
on adult ADHD was driven by self-referrals of adults who 
had symptoms of restlessness, impulsivity, and difﬁ  culty 
concentrating as well as psychosocial disability, as 
demonstrated by lower socioeconomic status or shorter job 
tenure.4,25 These adults met criteria for childhood onset ADHD 
but had never received this diagnosis.
The DSM-IV-TR ADHD symptoms of inattention in 
children include “often has difﬁ  culty sustaining attention 
in tasks or play activities; often seems not to be listening 
when spoken to directly; often does not follow through 
on instructions; often has difﬁ  culty organizing tasks and 
activities; often loses things necessary for tasks or activities; 
often is distracted easily by extraneous stimuli and is often 
forgetful in daily activities.” Symptoms of inattention in 
adults with ADHD include difﬁ  culty sustaining attention 
when reading or doing paperwork; distractibility and 
forgetfulness; poor concentration; poor time management; 
difﬁ  culty ﬁ  nishing tasks; and misplacing things.26
A similar migration occurs with hyperactive symptoms 
as a child with ADHD transitions into adulthood. The 
DSM-IV-TR symptoms of hyperactivity in children include 
“often ﬁ  dgets with hands or feet or squirms in seat; often 
runs about or climbs excessively in situations in which it 
is inappropriate; often has difﬁ  culty playing or engaging in 
leisure activities quietly; often ‘on the go’ or often acts as if 
‘driven by a motor’; and often talks excessively.”
In adults, symptoms of hyperactivity can present as 
feelings of restlessness or of being overwhelmed; choosing 
active jobs that require a lot of energy; working at multiple 
jobs; and talking excessively.26
As for impulsivity, childhood symptoms that present 
as “often blurts out answers before questions have been 
completed; often has difﬁ  culty awaiting turn; and often 
interrupts or intrudes on others (in conversation, in games)”, 
shift in adults and present as changing jobs impulsively; driv-
ing too fast; being involved in trafﬁ  c accidents; irritability; 
and being quick to anger.
Studies have since shown that childhood ADHD, if 
not effectively treated, increases the short- and long-term 
risk for many negative personal, social, family, vocational 
and health outcomes. These include cognitive difﬁ  culties 
(eg, inattention, disinhibition, slowed reaction time) 
which are associated with both ADHD and depression, 
interpersonal problems, school failure, failure to graduate,27–31 
substance misuse/abuse,13,24 legal difﬁ  culties, automobile 
accidents, workplace accidents, unemployment or under-
employment,13,24,28 lower socioeconomic status, family and 
marital difﬁ  culties,29,32 low self esteem, demoralization, 
and comorbid MDD.33–36 Biederman and colleagues found 
an increased incidence of alcohol (27%) and drug (18%) 
dependency compared to controls (13% and 6%, p  0.01 
and p  0.001, respectively) and statistically signiﬁ  cant rates 
of separation and divorce in adults with untreated ADHD 
(28%) compared to controls (15%, p  0.01).37
Key learning issue #2: ADHD 
and heritability
ADHD is highly heritable. Twin studies show the heritability 
of ADHD to be 0.80, indicating a substantial genetic effect, 
almost as high as that of schizophrenia (Table 1).38
There is some evidence that heritability is greater for 
ADHD that persists into young adulthood than for ADHD 
that remits in adolescence.38–40 A prospective four-year 
follow-up of ADHD diagnosed boys assessed in mid-
adolescence found that of those with persistent ADHD, the 
parental prevalence was 16.5% compared to 10.8% in those 
who had remitted. Similar results have been reported for 
ADHD in siblings.38
Children of parents with ADHD have up to a sevenfold 
increase in their risk for developing ADHD compared with 
children of non-ADHD parents.41 Although no single gene 
has been implicated in determining the expression of ADHD, 
recent studies have explored the effects of genes involved 
Table 1 Heritability of psychiatric disorders, respiratory disorders, 
and cancers
Heritability Reference
ADHD 0.80 Faraone 200036
Schizophrenia 0.83–0.87 Cardno et al 199981
Asthma 0.38 Palmer et al 200182
Prostate cancer 0.42 Palmer et al 200182
Colorectal cancer 0.35 Palmer et al 200182
Breast cancer 0.27 Palmer et al 200182
Abbreviation: ADHD, adult attention deﬁ  cit hyperactivity disorder.Neuropsychiatric Disease and Treatment 2009:5 140
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in the activities of dopamine receptors and transporter 
systems.6,12–16,41
Key learning issue #3: ADHD 
and comorbid depression
The literature search found strong evidence for the comorbidity 
of depression and ADHD but little in the way of tools to 
differentially diagnose and treat the disorders.6,7,34,36,42–48 
Comorbid depression occurs frequently in adult ADHD (see 
Table 2). According to the National Comorbidity Survey 
Replication study,8 the prevalence of MDD in adults with 
ADHD was 18.6% (SE 4.2) compared to 7.8% (SE 0.4) 
in non-ADHD respondents (OR 2.7). A more impressive, 
albeit less frequent, relationship was found for dysthymia 
(12.8% vs 1.9%, OR 7.5). Other investigators have reported 
similar results.5–7,24 The converse is also true. ADHD is 
found frequently in adult probands with depressive disorders. 
Reported rates range from 9%–16%.6,7,36,46
When ADHD and a depressive disorder present concur-
rently, individuals have been noted to be at a numerically 
greater risk (vs ADHD alone) for poorer long-term outcome 
(ie, negative social and vocational outcomes)49 and a higher 
numerical risk of suicide in children and adolescents.50,51 
There is a greater cost to society and individuals when ADHD 
occurs concurrently with depression.52–54 For example, 
patients with ADHD comorbid with another psychiatric 
disorder have been found to be more often unemployed 
than patients with ADHD alone, 34.5% versus 6.7%, 
respectively, although this was not a statistically signiﬁ  cant 
ﬁ  nding possibly due to a small sample size.48 Biederman 
and colleagues recently published an article that followed 
123 young females with ADHD and 122 female controls 
for ﬁ  ve years into adolescence/early adulthood. 40.7% of 
females with ADHD at baseline had MDD with moderate 
to severe impairment while only 11% of the controls had 
MDD. At the ﬁ  ve-year follow-up time point, 65% (80/123) 
of females with ADHD had MDD compared to 20.5% of 
controls. Even after adjustment for comorbid conditions, the 
relationship between ADHD and MDD was still signiﬁ  cant 
(95% conﬁ  dence interval 1.5–4.2; p  0.01).55
Few studies have directly addressed the functional 
consequences for adults with comorbid ADHD and 
depression. This is unsurprising considering it is only recently 
that ADHD has been considered a valid diagnosis for adults 
and work elucidating the relationships between ADHD and 
other psychiatric disorders is in its early stages. Studies in 
the pediatric setting have found that depressed children 
with ADHD were signiﬁ  cantly less socially competent than 
children with ADHD who were not depressed or community 
controls.56 Other earlier research conducted in young people 
suggests that the combination of affective and attention deﬁ  cit 
disorders may increase the risk for completed suicide,57 
increased suicidality,55 lead to poorer academic outcomes58 
and psychiatric hospitalization.55
Clinically, it is necessary to consider the possibility 
of comorbid depression in individuals diagnosed with 
ADHD and vice versa. However, it is important to carefully 
differentiate between the presence of a depressive syndrome 
and the presence of depressive symptoms that may arise 
secondarily to the demoralization or other negative emotional 
effects experienced by individuals as a consequence of 
ADHD.58–61 This distinction has important therapeutic 
considerations. ADHD-associated demoralization may be 
most parsimoniously treated with interventions primarily 
focused on addressing ADHD symptoms while treatment of 
a comorbid depressive disorder may require interventions for 
both disorders concurrently.60 The presence of concentration 
and memory problems, restlessness, irritability, anhedonia, 
and chronic difﬁ  culty getting and staying asleep may mimic 
depression. The panel concluded that it is not typical for 
ADHD in the absence of a mood disorder to be associated 
with a ﬁ  xed, depressed affect or suicidal thoughts. The 
majority of patients with ADHD maintain mood stability 
despite the social and occupational difﬁ  culties inherent to 
the disorder.
In summary, the onset of ADHD is pre-pubertal and 
persists into adulthood with up to 60% of those adults initially 
diagnosed with ADHD as children reporting clinically 
signiﬁ  cant symptoms of ADHD in adulthood. In the view of 
the panel, individuals who suffer from ADHD may not have 
been identiﬁ  ed or effectively treated in childhood and may 
present for the ﬁ  rst time to mental health care providers as 
adults, perhaps with complaints of depression or anxiety. In 
many of these individuals, their clinical presentation may be 
Table 2 Prevalence of depression comorbid with ADHD
Reference Prevalence of depression with ADHD
Biederman et al 200855 40.7%
Able et al 200721 31.0%
Kessler et al 20068 18.6%
Sobanski 200612 30%–50%a
Torgersen et al 200633 9% (Lifetime prevalence of 53%)
Fischer et al 200642 26%
Note: aOne or more past episodes of depression.
Abbreviation: ADHD, adult attention deﬁ  cit hyperactivity disorder.Neuropsychiatric Disease and Treatment 2009:5 141
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confounded by the secondary consequences of undiagnosed 
and untreated ADHD.
ADHD is heritable.38–40 The clinician should discuss the 
hereditary nature of ADHD and in the opinion of the panel; it 
is recommended that parents and/or children of the patient be 
screened for ADHD. Furthermore, although substantive data on 
this issue are not currently available, the panel concurs that effec-
tive treatment of parental ADHD may be expected to improve 
outcomes in the treatment of their children with ADHD.
Lastly, depression co-occurs with adult ADHD in 
9%–50% of cases and complicates the assessment and 
management of the patient.8,14,24,34,45
Diagnosing and treating ADHD 
comorbidity with depression 
assessment
There is limited information in the literature to help guide 
the clinician in assessing patients with comorbid conditions 
for ADHD and recommendations are made based on the 
panel’s clinical experience. The panel recommends, as part of 
a new patient interview, a general screen for the assessment 
of possible ADHD, even when there are other psychiatric 
presentations. The quick screen includes three questions:
1.  Have you ever been diagnosed with ADHD?
2.  Do you have a family history of ADHD?
3.  Did you have any difﬁ  culty in school?
Patients who screen positive for a previous diagnosis 
of ADHD, a family history of ADHD or reports of school 
difﬁ  culties characterized by behavioral or learning problems 
should undergo a more comprehensive review of current 
ADHD symptoms. This review should cover the three 
components of the ADHD spectrum:
1. Inattention.
2. Hyperactivity.
3. Impulsivity.
If symptoms are described, a more detailed review of 
the syndromal components of ADHD should follow. In 
addition, patients should be evaluated for the presence of 
functional impairment arising from these symptoms. As 
many clinicians have had limited training in the assessment 
and diagnosis of ADHD, the use of a validated screening 
aid such as the Adult Symptom Rating Scale (ASRS) (see 
http://www.med.nyu.edu/psych/psychiatrist/adhd.html)62 
may be useful. The ASRS may be used as part of the clinical 
interview or it can be completed at home after the interview, 
with corroboration from a parent, spouse, or close friend. In 
addition to its utility as a screening aid, the ASRS can also 
provide a useful baseline measure of symptom severity. 
The ASRS has not been validated as an evaluation tool to 
monitor symptom change, however, because the questions 
closely map the 18 items of the DSM-IV criteria, the panel 
suggests that the ASRS can be repeated during treatment to 
evaluate the outcome of an intervention.
The panel has developed an algorithm (Figure 1) to 
assist physicians in their diagnostic evaluation of any 
patient suspected of having ADHD, including patients with 
comorbidities like depression. Screening questions including 
mood, anxiety, psychotic and personality pathology are an 
essential part of any psychiatric interview. Likewise, a review 
of past and current medical history is important to rule out the 
impact of medical illness in the development or maintenance 
of any psychiatric disorder.
Panel recomendations 
on treatment
Psychostimulants (such as methylphenidate and amphetamine 
salts) and atomoxetine have been approved for the treatment 
of pediatric and adult ADHD in the United States and 
Canada. No pharmacological treatment for adult ADHD has 
been approved in the European Union (except for Ritalin 
LA in Norway). The antidepressants recommended for the 
treatment of major depression in this article are also approved 
for use in the United States, Canada and other countries. 
There are no antidepressants speciﬁ  cally indicated for MDD 
comorbid with ADHD.
ADHD treatment guidelines have focused primarily on 
pediatrics. Guidelines regarding the treatment of adult ADHD 
have appeared in the literature and online,63–65 however with 
limited information regarding practical pharmacotherapy 
treatment guidelines for co-occurring depression and 
ADHD.66–70
This article focuses on pharmacotherapy; however, Weiss 
and colleagues conducted a literature search for empirical 
studies of psychological treatment for adults with ADHD. 
Their search revealed ﬁ  ve empirical, short-term studies, 
which demonstrated, moderate to large effect sizes. However, 
there were inconsistencies in selection of control groups and 
measures of outcomes.71
ADHD with comorbid depression
The panel recommends clinicians use the guiding principle of 
treating the most severe or functionally impairing condition 
ﬁ  rst. If moderate-severe MDD is the most pressing clinical 
issue, then treatment for depression should be initiated ﬁ  rst. 
Clinicians may follow relevant clinical practice guidelines Neuropsychiatric Disease and Treatment 2009:5 142
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Screening questions for possible ADHD. 
Do you have a family history of ADHD (siblings, children, parents or extended family)?
Did you have any difficulty in school? Did you daydream or have difficulty paying attention? 
Did you get your homework done on time? Were you disruptive?
A POSITIVE ANSWER TO ONE OR MORE OF THESE THREE QUESTIONS 
SHOULD PROMPT THE CLINICIAN TO MOVE TO STEP 2 OF THIS ALGORITHM
Have you ever been diagnosed with ADHD?
Do you currently have substantial difficulties with forgetfulness, attention, impulsivity   
  or restlessness that are interfering with your relationships or your success at work?
If the answer is positive for BOTH STEP ONE AND STEP TWO then continue to refine 
the diagnosis of ADHD. 
1. Complete the Adult ADHD Self-Report Symptom Checklist (ASRS) 
STEP ONE
STEP TWO
DIAGNOSIS
There are two parts to the ASRS. If there are four or more checks in the darkened area 
of Part A then the patient has symptoms highly consistent with ADHD. Checks in the 
darkened areas of Part B provide additional cues and can serve as probes for further 
questioning. Reproduced in Appendix 1
2. Complete a diagnostic interview
A diagnosis of ADHD must meet DSM-IV or ICD-10 criteria, which are reproduced in
Appendix 2. 
Figure 1 Screening assessment.Neuropsychiatric Disease and Treatment 2009:5 143
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(in Canada, these would be CANMAT guidelines, see 
http://www.canmat.org).72 There has been increased focus 
by regulatory bodies on the risk of suicide in children and 
adolescents and patients should be monitored for indicators 
of potential suicidal ideation. Treatment of the depression 
may result in amelioration of the symptoms of frustration, 
anxiety, or irritability. Some cognitive symptoms such as 
concentration may also be improved with antidepressant 
treatment. Once the depression has improved, the patient 
should be re-evaluated for symptoms of ADHD and if 
necessary treatment for ADHD should be initiated. In 
the course of treating the depression, if a patient does 
not respond adequately to an antidepressant medication, 
consideration should be given to re-evaluating both the 
depression and ADHD diagnosis and, if appropriate, initiating 
ADHD treatment. Treatment goals must be established in 
collaboration with the patient and should include improving 
both symptoms and psychosocial functioning.
Combining medications used to treat depression and 
ADHD may result in drug-drug interactions of a pharmaco-
dynamic nature (ie, the medication’s effect on the body as 
evinced by competition for receptor binding) or pharmacoki-
netic nature (ie, the body’s effect on the medication as evinced 
by fatty foods slowing absorption of medications leading to 
higher plasma levels), although this is infrequent and there 
are no absolute contraindications except co-administration of 
psychostimulants or atomoxetine with monoamine oxidase 
inhibitors. A careful review of co-administered medications 
for potential drug–drug interactions is strongly advised. 
There is insufﬁ  cient data available to determine the best 
combination of antidepressant and ADHD treatment.70 The 
choice of treatment should be guided by clinical experience, 
knowledge of the pharmacokinetics of the various treatment 
options and other practical issues. Any of the ADHD agents 
may have behavioral side effects;73 hence there is a need to 
monitor the patient’s depressive state. Psychostimulants have 
been used as an augmentation strategy for treatment-resistant 
depression though with limited evidence for success.74,75
The panel recommends if ADHD is the primary dis-
abling condition and associated with mild depression, 
the ADHD should be treated ﬁ  rst. As mentioned previously, 
ADHD is often accompanied by distress, demoralization or 
mild depressive symptoms. These depressive symptoms may 
improve with ADHD treatment alone. The panel recommends 
a long acting psychostimulant as ﬁ  rst-line treatment for 
ADHD that is accompanied by distress, demoralization or 
mild depressive symptoms. The choice of agent should also 
be inﬂ  uenced by patient preference and risk proﬁ  le. Once the 
patient has been initiated on ADHD treatment, the depressive 
features should be reassessed at subsequent visits to deter-
mine if treatment for depression is warranted.
If both depression and ADHD are deemed equally clini-
cally relevant and functionally impairing the treatments may 
be initiated at close proximity. However, starting two treat-
ments simultaneously should be avoided if possible because 
if there are tolerability or efﬁ  cacy issues, it will be difﬁ  cult 
to determine which agent is responsible.
Additional diagnostic and treatment 
challenges
ADHD, anxiety symptoms, and anxiety 
disorders
An anxiety disorder (eg, obsessive compulsive disorder 
[OCD], post-traumatic stress disorder [PTSD], panic disorder 
[PD], generalized anxiety disorder [GAD]) and ADHD may 
co-occur and, in the opinion of the panel the same rules apply 
here as for major depression: the most severe or functionally 
impairing condition should be treated ﬁ  rst. However, patients 
with depression co-occurring with ADHD may present with 
anxiety symptoms that do not meet the criteria for an anxi-
ety disorder. Using simple screening questions for anxiety 
disorders when anxiety symptoms are present is necessary 
to determine how to properly manage these patients. Similar 
to depression, many patients with an anxiety disorder have 
difﬁ  culty with concentrating, memory, restlessness, and 
irritability, which are not associated with an underlying 
attention deﬁ  cit disorder. Some clues that the attention issue 
is paramount include the presence of symptoms less likely to 
be associated with anxiety such as stimulus-seeking behavior, 
disinhibition, or difﬁ  culty with time management.
Bipolar spectrum disorder
Bipolar disorder may occur comorbidly with ADHD, and has 
been reported to have an incidence of approximately 20% 
in adults with ADHD.8 Due to this possible relationship, 
patients with bipolar disorder should be screened for the pos-
sible presence of ADHD. This should be conducted during 
an euthymic phase as many symptoms of hypomania/mania 
also occur in ADHD. Any patient who experiences acute 
symptoms typical of mania or hypomania (eg, decreased 
need for sleep, increased energy, markedly inappropriate or 
erratic behavior, irritability, grandiosity, or psychotic symp-
toms) should be considered bipolar until proven otherwise. 
ADHD shares several of these symptoms, but is a chronic 
disorder unlikely to present with acute exacerbations and 
mood states are congruent.Neuropsychiatric Disease and Treatment 2009:5 144
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ADHD treatment and risk 
of substance use
Clinicians are often concerned that treating individuals 
with psychostimulants leads to substance misuse, abuse or 
diversion. The National Comorbidity Survey Replication 
study reports a 12-month incidence of comorbidity with sub-
stance use disorder of between 9.5% and 25.4%.8 Conversely, 
15%–25% of adults with substance use disorders present 
with ADHD.76 Although not all studies have shown the same 
results, the weight of information suggests that the risk of 
substance use disorders developing among individuals pre-
scribed psychostimulant medication for ADHD is reduced,77 
with some evidence that the treatment of ADHD may itself 
reduce the long-term risk for development of substance abuse 
disorders. A recent study suggested there was no protective 
effect associated with the treatment of ADHD; however 
patients treated with psychostimulants were no more likely 
to abuse substances than non-ADHD controls when they 
reached young adulthood.78
For patients with a history of substance abuse or 
dependence, the panel advises the use of short-acting 
stimulants should be avoided due to the possibility of misuse 
or diversion. Long-acting stimulants are effective and rela-
tively well tolerated for this patient population. Diversion 
does not appear to be an issue with atomoxetine. However, 
its onset of action is longer than the long-acting stimulants. 
If a patient exhibits comorbid substance abuse, then appro-
priate psychosocial substance abuse interventions should 
be implemented together with treatments for ADHD. Some 
patients actively abusing substances may present with atten-
tion, behavior and self-control problems that mimic ADHD. 
Depending on the nature and acuity of the substance abuse, 
the diagnosis of ADHD should be deferred until the substance 
abuse problems have stabilized, even with a positive child-
hood history.
Panel recommendations 
for treatment and monitoring
It is important to educate patients about the expected onset 
of treatment effects and the duration of treatment. The choice 
of medication for ADHD and depression is based on many 
factors including the patient’s informed choice, time of day 
when the impairment is most problematic, risk of substance 
abuse, the presence of other comorbid disorders, medication 
tolerability, history or likelihood of compliance, and cost. 
For optimal clinical management the panel suggests that 
it may take 7–10 days (sometimes sooner) to titrate to the 
appropriate dose of a psychostimulant to achieve maximal 
symptomatic improvement.79,80 Onset of response with 
atomoxetine may occur as early as two weeks; however, as 
noted in two identical 10 week studies, longer periods of 
time after obtaining the maximal dose appear to be required 
to obtain optimal response.81
At every treatment point, patients should be systematically 
evaluated regarding their symptoms of both ADHD and 
depression, including a review of side effects and psycho-
social functioning. Patient administered scales, which are 
helpful for both diagnosis and for monitoring response to 
treatment include the ASRS for ADHD and the Patient Health 
Questionnaire-9 (PHQ-9) (see http://www.depressionpri-
marycare.org/clinicians/toolkits/materials/forms/phq9/) for 
depression. The panel recommends monitoring of pulse and 
blood pressure at initiation of treatment, at dose changes and 
periodically, at regular intervals, thereafter. The introduction 
of medication will usually lead to symptom improvement, 
but symptomatic remission along with functional recovery 
is an endpoint that usually requires both medication and 
psychosocial interventions. It is unlikely that either ADHD 
or depression will remit if both disorders are not considered 
in the treatment plan.
Absence of improvement of ADHD
If there has been no substantial improvement in ADHD 
symptoms after at least two weeks at the maximal tolerable 
dose of the ﬁ  rst medication, a trial of an agent from another 
class is warranted (eg, methylphenidate switched to mixed 
amphetamine salts or vice versa), or to a medication outside 
the psychostimulant class (eg, atomoxetine). If a second trial 
does not signiﬁ  cantly alleviate symptoms, reevaluation of the 
diagnosis and potential comorbidities should be completed. If 
the ADHD diagnosis is conﬁ  rmed and no untreated comorbid 
conditions are evident, consultation with an ADHD treatment 
specialist, if available, should be sought.
Adults with ADHD should be encouraged to address 
elements in their life that may contribute to improved treatment 
outcomes. These include decreasing the consumption of 
caffeine-containing beverages (eg, coffee, tea, colas, etc); 
improve sleep hygiene (regular bedtime, stimulus decreasing 
activities prior to bed, quiet and cool sleeping environment); 
and daily exercise or relaxation activities.
Cardiovascular concerns about 
stimulant use in adults
The American Heart Association and the American Academy 
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regarding cardiac risk and need for cardiac evaluation with 
respect to prescribing medication for ADHD.82 The associa-
tions both agreed that medications used to treat ADHD have 
not been shown to cause heart conditions nor have they been 
demonstrated to cause sudden cardiac death. However, some 
of these medications can “increase or decrease heart rate 
and blood pressure” although this is not usually considered 
to be dangerous.
The joint advisory also clariﬁ  ed the AHA/AAP position 
on the necessity of ordering ECGs before treating ADHD. 
The advisory read that it is, “… prudent to carefully assess 
children for heart conditions who need to receive treatment 
with drugs for ADHD.” As well, they recommended obtaining 
a patient and family health history and conducting a physical 
exam focused on cardiovascular disease risk factors before 
treatment with medications for ADHD. The joint statement 
said that acquiring an electrocardiogram (ECG) should be at 
the physician’s judgment, and it is not mandatory to obtain 
one. The statement went on to suggest that, “… treatment of 
ADHD should not be withheld because an ECG is not done.”82 
While these recommendations were made with respect to 
children, it is the opinion of the panel that the same should 
hold true for adults being treated with ADHD medication 
(ie, treatment should not be withheld in the absence of an 
ECG). Central nervous system stimulant medications should 
be used with caution in adults with pre-existing cardiovascular 
or cerebrovascular conditions and should not be used in 
symptomatic cardiovascular disease or in people with known 
structural abnormalities.83 The recommendations above are 
applicable to stimulants and nonstimulant treatments for 
ADHD, including atomoxetine.
The panel recommends that if after having conducted 
the AHA recommended investigations, the physician is 
uncomfortable with prescribing treatment for ADHD due to 
possible cardiac risk: a referral to a cardiologist is warranted. 
Treatment should not be avoided due to potential risk, but 
may be delayed until a cardiology opinion is obtained. It is 
the panel’s opinion that heart rate and blood pressure should 
be assessed before treatment commences, following each 
dose change, and as clinically indicated.
Summary
Although not well appreciated by many clinicians, adult 
ADHD is a complex and relatively common psychiatric 
disorder that has substantial impact on social, personal, 
and vocational functioning and wellness.13,24,28–31 ADHD 
frequently may present comorbidly with depressive disorders, 
which worsens the morbidity of both disorders.6,7,34,36,42–47 
Individuals with comorbid ADHD and depression should 
have both disorders identiﬁ  ed, diagnosed and treated to 
optimize outcomes. To summarize, the panel recommends a 
general screen for adult ADHD for all new patients presenting 
in a physician’s ofﬁ  ce. Symptoms of adult ADHD may 
overlap those of affective disorders or be “hidden” by the 
more severe condition. Tests for ADHD and MDD are tools 
that may improve diagnostic consideration of these condi-
tions and may also be used to evaluate symptom improvement 
if indicated. Clinically, the ﬁ  rst intervention is to treat the 
condition with the greatest impact on patient function. If the 
patient presents with suicidal ideation, then an assessment 
for MDD should occur and if MDD is conﬁ  rmed, treatment 
should begin. If the patient presents with deﬁ  cits in function 
due to the inability to concentrate at work, complete tasks, or 
forgetfulness as the most severe presenting condition in addi-
tion to a mild depression, and the diagnostic assessment leads 
to adult ADHD, then the ADHD should be treated ﬁ  rst.
Some patients may present with attention, behavioral 
and self-control problems that mimic ADHD but are due to 
actively abusing substances. Depending on the nature and 
acuity of the substance abuse, the diagnosis and treatment of 
ADHD should be deferred until the substance abuse problems 
have stabilized.
Conclusion
This article provides clinicians with a clinically relevant 
overview of the literature pertaining to comorbid ADHD 
and depression and offers a clinically useful diagnostic 
algorithm and treatment suggestions. Appropriate diagnosis 
and application of effective treatments, in the opinion of the 
panel can be expected to substantially improve both short- 
and long-term outcomes for patients with comorbid ADHD 
and depression. Further research is needed to clarify what 
are the best tolerated and effective medication combinations 
for comorbid depression and ADHD.
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Appendix 1
Adult ADHD Self-Report Scale (ASRS-v1.1)
symptom checklist instructions
The questions on the back page are designed to stimulate 
dialogue between you and your patients and to help conﬁ  rm 
if they may be suffering from the symptoms ofattention-deﬁ  cit/
hyperactivity disorder (ADHD).
Description: The symptom checklist is an instrument consist-
ing of the eighteen DSM-IV-TR criteria. Six of the eighteen 
questions were found to be the most predictive of symptoms 
consistent with ADHD. These six questions are the basis for 
the ASRS v1.1 Screener and are also Part A of the symptom 
checklist. Part B of the symptom checklist contains the 
remaining twelve questions.
Instructions
Symptoms
1.  Ask the patient to complete both Part A and Part B of 
the symptom checklist by marking an X in the box that 
most closely represents the frequency of occurrence of 
each of the symptoms.
2.  Score Part A. If four or more marks appear in the darkly 
shaded boxes within Part A then the patient has symp-
toms highly consistent with ADHD in adults and further 
investigation is warranted.
3.  The frequency scores on Part B provide additional cues 
and can serve as further probes into the patient’s symp-
toms. Pay particular attention to marks appearing in the 
dark shaded boxes. The frequency-based response is 
more sensitive with certain questions. No total score or 
diagnostic likelihood is utilized for the twelve questions. 
It has been found that the six questions in Part A are the 
most predictive of the disorder and are best for use as a 
screening instrument.
Impairments
1.  Review the entire symptom checklist with your patients 
and evaluate the level of impairment associated with the 
symptom.
2.  Consider work/school, social and family settings.
3.  Symptom frequency is often associated with symptom 
severity, therefore the symptom checklist may also aid 
in the assessment of impairments. If your patients have 
frequent symptoms, you may want to ask them to describe 
how these problems have affected the ability to work, take 
care of things at home, or get along with other people 
such as their spouse/signiﬁ  cant other.
History
1.  Assess the presence of these symptoms or similar symp-
toms in childhood. Adults who have ADHD need not 
have been formally diagnosed in childhood. In evaluating 
a patient’s history, look for evidence of early-appearing 
and long-standing problems with attention or self-control. 
Some signiﬁ  cant symptoms should have been present in 
childhood, but full symptomology is not necessary.Neuropsychiatric Disease and Treatment 2009:5 149
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Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist
Patient name Today’s date
Please answer the questions below, rating yourself on each of the criteria shown using the scale on the right side of 
the page. As you answer each question, place an X in the box that best describes how you have felt and conducted 
yourself over the past 6 months. Please give this completed checklist to your healthcare professional to discuss 
during today’s appointment.
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1.   How often do you have trouble wrapping up the ﬁ  nal details of a project, once the challenging parts have been done?
2.   How often do you have difﬁ  culty getting things in order when you have to do a task that requires organization?
3.   How often do you have problems remembering appointments or obligations?
4.   When you have a task that requires a lot of thought, how often do you avoid or delay getting started?
5.   How often do you ﬁ  dget or squirm with your hands or feet when you have to sit down for a long time?
6.   How often do you feel overly active and compelled to do things, like you were driven by a motor?
part A
7.   How often do you make careless mistakes when you have to work on a boring or difﬁ  cult project?
8.   How often do you have difﬁ  culty keeping your attention when you are doing boring or repetitive work?
9.   How often do you have difﬁ  culty concentrating on what people say to you, even when they are speaking to you 
directly?
10.   How often do you misplace or have difﬁ  culty ﬁ  nding things at home or at work?
11.   How often are you distracted by activity or noise around you?
12.   How often do you leave your seat in meetings or other situations in which you are expected to remain seated?
13.   How often do you feel restless or ﬁ  dgety?
14.   How often do you have difﬁ  culty unwinding and relaxing when you have time to yourself?
15.   How often do you ﬁ  nd yourself talking too much when you are in social situations?
16.   When you’re in a conversation, how often do you ﬁ  nd yourself ﬁ  nishing the sentences of the people you are 
talking to, before they can ﬁ  nish them themselves?
17.   How often do you have difﬁ  culty waiting your turn in situations when turn taking is required?
18.   How often do you interrupt others when they are busy?
Part B
The value of screening for adults 
with ADHD
Research suggests that the symptoms of ADHD can persist 
into adulthood, having a signiﬁ  cant impact on the relation-
ships, careers, and even the personal safety of your patients 
who may suffer from it.1–4 Because this disorder is often 
misunderstood, many people who have it do not receive 
appropriate treatment and, as a result, may never reach their 
full potential. Part of the problem is that it can be difﬁ  cult 
to diagnose, particularly in adults.
The Adult ADHD Self-Report Scale (ASRS-v1.1) symp-
tom checklist was developed in conjunction with the World 
Health Organization (WHO), and the Workgroup on Adult 
ADHD that included the following team of psychiatrists 
and researchers:
•   Lenard Adler, MD
  Associate Professor of Psychiatry and Neurology
  New York University Medical School
•  Ronald C. Kessler, PhD
  Professor, Department of Health Care Policy
  Harvard Medical School
•  Thomas Spencer, MD
 Associate  Professor  of  Psychiatry
  Harvard Medical School
As a healthcare professional, you can use the ASRS v1.1 
as a tool to help screen for ADHD in adult patients. Insights 
gained through this screening may suggest the need for a more 
in-depth clinician interview. The questions in the ASRS v1.1 
are consistent with DSM-IV criteria and address the manifes-
tations of ADHD symptoms in adults. Content of the ques-
tionnaire also reﬂ  ects the importance that DSM-IV places on 
symptoms, impairments, and history for a correc diagnosis.4
The checklist takes about ﬁ  ve minutes to complete and 
can provide information that is critical to supplement the 
diagnostic process.
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Appendix 2
ICD-10 Criteria for Diagnosis of Hyperkinetic Disorders.
Reproduced with permission from: World Health Organiza-
tion. The ICD-10 Classiﬁ  cation of mental and behavioural 
disorders: Diagnostic Criteria for Research. Geneva: Author, 
1993, p155–157.
F90. Hyperkinetic disorders.
Note: The research diagnosis of hyperkinetic disorder 
requires the deﬁ  nite presence of abnormal levels of inatten-
tion, hyperactivity, and restlessness that are pervasive across 
situations and persistent over time and that are not caused by 
other disorders such as autism or affective disorders.
G1. Inattention. At least six of the following symptoms of 
inattention have persisted for at least six months, to a degree 
that is maladaptive and inconsistent with the developmental 
level of the child:
1.  often fails to give close attention to details, or makes 
careless errors in schoolwork, work, or other activities;
2.  often fails to sustain attention in tasks or play activities;
3.  often appears not to listen to what is being said to him 
or her;
4.  often fails to follow through on instructions or to ﬁ  n-
ish schoolwork, chores, or duties in the workplace (not 
because of oppositional behaviour or failure to understand 
instructions);
5.  is often impaired in organizing tasks and activities;
6.  often avoids or strongly dislikes tasks, such as homework, 
that require sustained mental effort;
7.  often loses things necessary for certain tasks or activities, 
such as school assignments, pencils, books, toys, or tools;
8.  is often easily distracted by external stimuli;
9.  is often forgetful in the course of daily activities.
G2. Hyperactivity. At least three of the following symptoms 
of hyperactivity have persisted for at least 6 months, to a 
degree that is maladaptive and inconsistent with the devel-
opmental level of the child:
1. often  ﬁ  dgets with hands or feet or squirms on seat;
2.  leaves seat in classroom or in other situations in which 
remaining seated is expected;
3.  often runs about or climbs excessively in situations in 
which it is inappropriate (in adolescents or adults, only 
feelings of restlessness may be present);
4.  is often unduly noisy in playing or has difﬁ  culty in engag-
ing quietly in leisure activities;
5.  exhibits a persistent pattern of excessive motor activity 
that is not substantially modiﬁ  ed by social context or 
demands.
G3. Impulsivity. At least one of the following symptoms of 
impulsivity has persisted for at least 6 months, to a degree 
that is maladaptive and inconsistent with the development 
level of the child:
1.  often blurts out answers before questions have been 
completed;
2.  often fails to wait in lines or await turns in games or group 
situations;
3.  often interrupts or intrudes on others (eg, butts into others’ 
conversations or games);
4.  often talks excessively without appropriate response to 
social constraints.
G5. Onset of the disorder is no later than the age of 7 years.
G5. Pervasiveness. The criteria should be met for more than a 
single situation, eg, the combination of inattention and hyper-
activity should be present both at home and at school, or at 
both school and another setting where children are observed, 
such as a clinic. (Evidence for cross-situationality will 
ordinarily require information from more than one source; 
parental reports about classroom behaviour, for instance, are 
unlikely to be sufﬁ  cient).
G6. The symptoms in G1–G3 cause clinically signiﬁ  cant 
distress or impairment I social, academic, or occupational 
functioning.
G7. The disorder does not meet the criteria for pervasive 
developmental disorders (F84.-), manic episode (F30.-), 
depressive episode (F32.-), or anxiety disorders (F41.-).
Comment
Many authorities also recognise conditions that are sub-
threshold for hyperkinetic disorder. Children who meet 
criteria in other ways but do not show abnormalities of 
hyperactivity/impulsiveness may be recognized as showing 
attention deﬁ  cit; conversely, children who fall short of criteria 
for attention problems but meet criteria in other respect may 
be recognized as showing activity disorder. In the same way, 
children who meet criteria for only one situation (eg, only the 
whom or only the classroom) may be regarded as showing a 
home-speciﬁ  c or classroom-speciﬁ  c disorder. These condi-
tions are not yet included in the main classiﬁ  cation because 
of insufﬁ  cient empirical predictive validation, and because 
many children with sub-threshold disorders show other 
syndromes (such as oppositional deﬁ  ant disorder, F91.3) and 
should be classiﬁ  ed in the appropriate category.
F90.0 Disturbance of activity and attention.
The general criteria for hyperkinetic disorder (F90) must 
be met, but not those for conduct disorders (F91.-).